Genital herpes is a recurrent lifelong disease with no cure, caused by herpes simplex virus (HSV).
HSV-2 is usually the cause but HSV-1 may occur in up to 1/3 of new cases.
HSV-1 tends to cause fewer recurrences & milder disease than HSV-2.
The incubation period is 2 days-2 weeks after exposure.

Genital%20herpes Diagnosis


Classification of Genital Herpes Simplex Virus Infection

  • Initial Episode
    • Primary HSV
      • First infection with either HSV-1 or HSV-2 in individuals who do not have antibodies to either HSV-1 or HSV-2
      • Associated with more extensive genital lesions, systemic symptoms, complications, and duration of symptoms
      • More severe infections (ie duration >35 days) have 2x more often recurrent episodes with shorter interval from 1st recurrence
    • Non-primary HSV
      • First infection with either HSV-1 or HSV-2 in individuals who have previously existing antibodies against HSV-2 and HSV-1 respectively
      • Less likely to develop constitutional or severe symptoms
  • Recurrent HSV
    • Results from reactivation of latent virus
    • Milder, more localized, lesser viral shedding and shorter duration as opposed to primary infection
    • After symptomatic 1st episode of genital HSV infection, median recurrence rate is 0.34 recurrences/month for HSV-2, and is 4 times more common than in HSV-1 infected patients
    • Rate of recurrences decreases over time in most patients
    • Usually brought about by triggering factors (eg UV light, immunosuppression, trauma, stress)

Physical Examination

Clinical Manifestations

  • Infection is frequently asymptomatic
  • Local symptoms: Pain, itching, dysuria, vaginal and urethral discharge and tender inguinal lymphadenopathy
  • Systemic symptoms: Fever, headache, myalgia, abdominal pain
  • Lesions may be present in varying stages (vesicles, blisters or ulcers)
    • Can occur on the vulva, cervix, vagina, urethral or perianal skin and extragenital areas (eg buttocks, thighs or perineum)
    • Painful and contains large amount of infectious viral particles which are excreted over 3 weeks
  • More severe infections and higher rate of complications in women during the primary infection
    • May be due to larger surface area affected in females and ability of the virus to easily spread over moist surfaces
  • Systemic complications: Urinary retention syndrome, aseptic meningitis, transverse myelitis, sacral radiculopathy, extragenital lesions (buttocks, perineum or thighs), disseminated infections and superinfection with bacteria or fungi
  • Mean duration of symptoms: 16.5-22.7, 15.5, and 9.3-10.6 days in primary, non-primary, and recurrent episodes, respectively

Clinical Manifestations that may Require Hospitalization

  • Urinary retention
  • Severe constitutional symptoms
  • Disseminated infection
  • Meningitis

Laboratory Tests

Viral Detection

  • Should be done to all patients with suspected genital herpes who were not previously diagnosed with HSV
  • Performed best with early lesions
  • Lack of HSV detection does not indicate absence of HSV infection because viral shedding is intermittent
    • As HSV shedding is intermittent, testing swabs for routine diagnosis is not recommended in asymptomatic patients as confirmation of carrier status is unlikely

Viral Culture

  • Isolate of HSV in cell culture
  • Both sensitive and specific, but sensitivity is lower for recurrent lesions and decreases as lesions heal (70% from ulcers, 94% from vesicles)
  • Virus isolates can be distinguished and tested for antiviral susceptibility
  • However, results are slow and labor intensive

Cytological Exam

  • Eg Tzanck and Papanicolaou smears
  • with moderate specificity and sensitivity
  • Not recommended for diagnosis except in limited-resource settings

Viral Antigen Detection Tests

  • Eg Direct immunofluorescence assay (IFA) or enzyme immunoassay (EIA)
  • Less sensitive than virus culture and generally not recommended except in limited-resource settings
  • EIA may be used as a rapid alternative diagnostic test in symptomatic patients where laboratory facilities are limited
  • Reports HSV type when test is positive

Polymerase Chain Reactions (PCR)

  • Test for HSV DNA; allows viral typing
    • HSV DNA is considered the diagnostic gold standard 
  • HSV detection rates are increased compared with virus culture
  • Highly sensitive and specific, but costly, inaccessible, and labor intensive
  • Test of choice in diagnosing CNS HSV infection

Type-Specific Serologic Tests (TSST)

  • Type-specific assay for HSV antibodies, eg Western blot
  • Not routinely recommended in asymptomatic patients but useful in recurrent or atypical genital symptoms with negative direct virus detection methods; clinical diagnosis of genital herpes without laboratory evidence; 1st-episode genital herpes where primary and established infection differentiation guides disease management; for patients with genital herpes-infected partner or sexual partners of genital herpes-infected patient; and for seroepidemiological studies
  • Do not distinguish anogenital from orolabial infection in the presence of HSV-1 antibodies
  • Detection of HSV-2 antibody in most cases indicates anogenital infection
  • Repeat serologic testing after 3 months is advised in patients with suspected recent infection who have negative HSV antibody early after presentation
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Diagnosis of heart diseases has abruptly and significantly decreased across the globe due to the coronavirus disease 2019 (COVID-19) pandemic, especially affecting poorer countries, reveals a study.
Pearl Toh, -18 hours ago
While it is well known that COVID-19 illness is associated with coagulopathy, the optimal anticoagulation strategy remains elusive, and two studies presented at the ASH 2020 Congress further add to the growing debate on the appropriate anticoagulant dose for hospitalized patients with COVID-19.